Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1991 2
1995 3
1996 1
1999 3
2000 2
2002 2
2003 1
2004 4
2006 1
2008 1
2009 1
2012 1
2013 2
2014 1
2015 1
2016 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Sjögren's syndrome with pleural effusion.
Ogihara T, Nakatani A, Ito H, Irokawa M, Ban S, Takahashi A, Nishinarita M, Oka Y. Ogihara T, et al. Among authors: nishinarita m. Intern Med. 1995 Aug;34(8):811-4. doi: 10.2169/internalmedicine.34.811. Intern Med. 1995. PMID: 8563128 Free article.
Efficacy and safety of rebamipide for the treatment of dry mouth symptoms in patients with Sjögren's syndrome: a double-blind placebo-controlled multicenter trial.
Sugai S, Takahashi H, Ohta S, Nishinarita M, Takei M, Sawada S, Yamaji K, Oka H, Umehara H, Koni I, Sugiyama E, Nishiyama S, Kawakami A. Sugai S, et al. Among authors: nishinarita m. Mod Rheumatol. 2009;19(2):114-24. doi: 10.1007/s10165-008-0141-1. Epub 2008 Dec 17. Mod Rheumatol. 2009. PMID: 19089532 Free article. Clinical Trial.
Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity-results from the ENCOURAGE study, a prospective, international, multicenter randomized study.
Yamanaka H, Nagaoka S, Lee SK, Bae SC, Kasama T, Kobayashi H, Nishioka Y, Ueki Y, Seto Y, Nishinarita M, Tamura N, Kimura N, Saito K, Tomita T, Nawata Y, Suzuki S, Ishigatsubo Y, Munakata Y, Makino Y, Inoue E, Tanaka Y, Takeuchi T; ENCOURAGE study group. Yamanaka H, et al. Among authors: nishinarita m. Mod Rheumatol. 2016 Sep;26(5):651-61. doi: 10.3109/14397595.2015.1123349. Epub 2015 Dec 23. Mod Rheumatol. 2016. PMID: 26698929 Clinical Trial.
Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial.
Hara M, Ishiguro N, Katayama K, Kondo M, Sumida T, Mimori T, Soen S, Nagai K, Yamaguchi T, Yamamoto K; Iguratimod-Clinical Study Group. Hara M, et al. Mod Rheumatol. 2014 May;24(3):410-8. doi: 10.3109/14397595.2013.843756. Epub 2013 Nov 7. Mod Rheumatol. 2014. PMID: 24252050 Clinical Trial.
24 results